Ocugen Provides Business Update with First Quarter 2025 Financial Results
May 9, 2025
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA(TM) Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
March 31, 2022
Related Post
-
-
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 7, 2025
-
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
May 7, 2025
-
Pacaso — The $1.3 Trillion Secret That Everyday Investors Are Finally Invited To
May 6, 2025